Charles River Laboratories Intl. Inc (NYSE:CRL) – Stock analysts at KeyCorp issued their Q1 2018 earnings estimates for shares of Charles River Laboratories Intl. in a research report issued to clients and investors on Tuesday. KeyCorp analyst D. Hooker forecasts that the medical research company will earn $1.24 per share for the quarter. KeyCorp also issued estimates for Charles River Laboratories Intl.’s Q2 2018 earnings at $1.43 EPS, Q3 2018 earnings at $1.38 EPS, Q4 2018 earnings at $1.44 EPS, FY2018 earnings at $5.49 EPS and FY2019 earnings at $6.09 EPS.

Several other analysts also recently issued reports on CRL. Zacks Investment Research raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research note on Tuesday, October 24th. Bank of America decreased their price objective on shares of Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, November 10th. ValuEngine downgraded shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Robert W. Baird set a $117.00 price objective on shares of Charles River Laboratories Intl. and gave the stock a “buy” rating in a research note on Monday, November 13th. Finally, SunTrust Banks reissued a “buy” rating and issued a $113.00 price objective on shares of Charles River Laboratories Intl. in a research note on Friday, November 17th. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $114.85.

Shares of Charles River Laboratories Intl. (NYSE CRL) opened at $110.31 on Thursday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.62. The stock has a market cap of $5,106.20, a PE ratio of 43.43, a price-to-earnings-growth ratio of 1.60 and a beta of 0.74. Charles River Laboratories Intl. has a 12 month low of $86.25 and a 12 month high of $119.05.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.14. The business had revenue of $478.50 million during the quarter, compared to the consensus estimate of $475.02 million. Charles River Laboratories Intl. had a net margin of 6.64% and a return on equity of 26.14%. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 earnings per share.

In other news, Chairman James C. Foster sold 4,967 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $109.44, for a total transaction of $543,588.48. Following the transaction, the chairman now directly owns 329,928 shares of the company’s stock, valued at $36,107,320.32. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Online Communications Bdirect sold 131,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $0.29, for a total transaction of $37,990.00. Over the last ninety days, insiders have sold 195,673 shares of company stock worth $2,644,046. Corporate insiders own 2.20% of the company’s stock.

Several large investors have recently modified their holdings of the company. Lord Abbett & CO. LLC purchased a new position in Charles River Laboratories Intl. during the second quarter valued at approximately $65,915,000. TimesSquare Capital Management LLC increased its holdings in Charles River Laboratories Intl. by 181.1% during the fourth quarter. TimesSquare Capital Management LLC now owns 915,600 shares of the medical research company’s stock valued at $100,212,000 after buying an additional 589,900 shares during the period. Mackenzie Financial Corp increased its holdings in Charles River Laboratories Intl. by 81.7% during the third quarter. Mackenzie Financial Corp now owns 928,796 shares of the medical research company’s stock valued at $100,329,000 after buying an additional 417,739 shares during the period. APG Asset Management N.V. increased its holdings in Charles River Laboratories Intl. by 261.2% during the fourth quarter. APG Asset Management N.V. now owns 368,800 shares of the medical research company’s stock valued at $33,615,000 after buying an additional 266,700 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Charles River Laboratories Intl. by 147.8% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 424,480 shares of the medical research company’s stock valued at $46,459,000 after buying an additional 253,180 shares during the period. 97.13% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Charles River Laboratories Intl. Inc to Post Q1 2018 Earnings of $1.24 Per Share, KeyCorp Forecasts (CRL)” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://theolympiareport.com/2018/02/15/charles-river-laboratories-intl-inc-to-post-q1-2018-earnings-of-1-24-per-share-keycorp-forecasts-crl.html.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.